ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNG Synairgen Plc

4.675
0.00 (0.00%)
Last Updated: 08:00:27
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.675 4.36 4.99 - 38,838 08:00:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.53 9.41M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.68p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.41 million. Synairgen has a price to earnings ratio (PE ratio) of -0.53.

Synairgen Share Discussion Threads

Showing 2026 to 2045 of 99175 messages
Chat Pages: Latest  91  90  89  88  87  86  85  84  83  82  81  80  Older
DateSubjectAuthorDiscuss
02/4/2020
08:47
I so hurt I have been filtered. You obviously cannot deal with someone that you cannot ban and who is tolerant and democratic. At the end of the day I am here for one reason and one reason only to make money that is why I hold SNG and a fair chunk of them as well.
vitec
02/4/2020
08:44
Vitec ....it was fake news... don't you understand?
kop202
02/4/2020
08:44
Vitec filtered.
arpy2
02/4/2020
08:37
What would have happened is that he would have kept on dredging up whatever dubious information he could find which at best would have been only vaguely relevant. He is an insidious if educated individual. His motives were not to save us all I can assure you.
nobbygnome
02/4/2020
08:30
Banning dissenters, those that post alternative views can be counter productive. Strength of opinion and argument should be borne out be the evidence presented. If SNG001 is so good (i believe it is) the evidence will speak for itself and destroy any alternative view that differs.
vitec
02/4/2020
08:28
Yes he was a troll of mine albeit subtle one who is actually quite well informed. But I know his game so better to nip it in the bud!
nobbygnome
02/4/2020
08:23
Yes I think this banning thing really seems to be getting at some .
There 's a new thread completely devoted to sour grapes, of such, which shows it's working.

Chuckle.

hazl
02/4/2020
08:17
A grudge poster against Nobby for some of Nobby's home truths on IMM.

Best ignored.

jev1
02/4/2020
08:11
Bell end godd bye
jrlomax
02/4/2020
08:07
Why are you copy and pasting things that are ten years old and completely irrelevant to today's product , we're you born a idiot or just woke up like it .,.............
tialouise
02/4/2020
08:06
Think you need to carry on reading the Company news releases rather than stopping at 2012.

Not sure if you have noticed they are dosing patients in NHS wards with SNG-001 now.

talk2dubya
02/4/2020
08:03
Anyone have a detailed analytical view on this previous Synairgen SNG-001 FAILED clinical trial?

... IFN-β treatment had no significant effect on this primary endpoint ...

ClinicalTrials.gov Identifier: NCT01126177

Recruitment Status : Completed
First Posted : May 19, 2010
Last Update Posted : February 13, 2012

Sponsor:
Synairgen Research Ltd

Study Design
Go to sections
Study Type : Interventional (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled Phase II Study, Comparing the Efficacy and Safety of Inhaled SNG001 to Placebo Administered to Asthmatic Subjects After the Onset of a Respiratory Viral Infection for the Prevention or Attenuation of Asthma Symptoms Caused by Respiratory Viruses
Study Start Date : March 2010
Actual Primary Completion Date : October 2011
Actual Study Completion Date : January 2012


Am J Respir Crit Care Med. 2014 Jul 15;190(2):145-54. doi: 10.1164/rccm.201312-2235OC

The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial.

Djukanović R1, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, Niven R, Singh D, Reddel HK, Davies DE, Marsden R, Boxall C, Dudley S, Plagnol V, Holgate ST, Monk P; INTERCIA Study Group.
Collaborators (28)
Author information
Abstract
RATIONALE:
Ex vivo, bronchial epithelial cells from people with asthma are more susceptible to rhinovirus infection caused by deficient induction of the antiviral protein, IFN-β. Exogenous IFN-β restores antiviral activity.
OBJECTIVES:
To compare the efficacy and safety of inhaled IFN-β with placebo administered to people with asthma after onset of cold symptoms to prevent or attenuate asthma symptoms caused by respiratory viruses.
METHODS:
A total of 147 people with asthma on inhaled corticosteroids (British Thoracic Society Steps 2-5), with a history of virus-associated exacerbations, were randomized to 14-day treatment with inhaled IFN-β (n = 72) or placebo (n = 75) within 24 hours of developing cold symptoms and were assessed clinically, with relevant samples collected to assess virus infection and antiviral responses.
MEASUREMENTS AND MAIN RESULTS:
A total of 91% of randomized patients developed a defined cold. In this modified intention-to-treat population, asthma symptoms did not get clinically significantly worse (mean change in six-item Asthma Control Questionnaire <0.5) and IFN-β treatment had no significant effect on this primary endpoint, although it enhanced morning peak expiratory flow recovery (P = 0.033), reduced the need for additional treatment, and boosted innate immunity as assessed by blood and sputum biomarkers. In an exploratory analysis of the subset of more difficult-to-treat, Step 4-5 people with asthma (n = 27 IFN-β; n = 31 placebo), Asthma Control Questionnaire-6 increased significantly on placebo; this was prevented by IFN-β (P = 0.004).
CONCLUSIONS:
Although the trial did not meet its primary endpoint, it suggests that inhaled IFN-β is a potential treatment for virus-induced deteriorations of asthma in difficult-to-treat people with asthma and supports the need for further, adequately powered, trials in this population. Clinical trial registered with www.clinicaltrials.gov (NCT 01126177).





Edit: I may be late to the party and not found the previous responses but is that a reason to provide a go away answer?
I thought you wanted a range of information on this thread Nobby.
You seem to prefer to surround yourself with sycophants.
I do not “troll” anyone on ADFN, or anywhere else for that matter, I challenge anyone to find a single instance.

borromini1
02/4/2020
08:00
Also makes it feel real seeing a respiratory nurse talking (and clearly being excited) about it.

Shares run on sentiment if nothing else, SNG are front and centre of this fight all good stuff.

talk2dubya
02/4/2020
07:58
I think it shows that recruiting the 100 patients quickly will be no issue once all the sites are up and running!
nobbygnome
02/4/2020
07:58
Opening with quite a spread this morning 7.9%, that will be a costly buy or sell
makendon
02/4/2020
07:56
Here you are with full credit to oby_1 who sent it to me.
nobbygnome
02/4/2020
07:54
Treated as in made better or dosed?
talk2dubya
02/4/2020
07:54
I want to let the person who discovered it post it....
nobbygnome
02/4/2020
07:52
“I am hearing some rumours that quite a few patients have already been treated in Southampton. I will let the person who discovered it post the evidence...”

Come on then, let’s hear the evidence...

74tom
02/4/2020
07:47
The time they spend in hospital is also key when there is a bed shortage. Of course some will be treated at home but I suspect most won't.
nobbygnome
Chat Pages: Latest  91  90  89  88  87  86  85  84  83  82  81  80  Older

Your Recent History

Delayed Upgrade Clock